Key statistics
On Friday, Evaxion Biotech A/S (EVAX:NAQ) closed at 2.99, 32.30% above the 52 week low of 2.26 set on Jun 17, 2024.
52-week range
Open | 3.29 |
---|---|
High | 3.31 |
Low | 2.92 |
Bid | 2.90 |
Offer | 3.34 |
Previous close | 3.15 |
Average volume | 85.70k |
---|---|
Shares outstanding | 557.61k |
Free float | -- |
P/E (TTM) | -- |
Market cap | 16.67m USD |
EPS (TTM) | -36.98 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 20:59 BST.
More ▼
- Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
- Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
- Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
- Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results
- Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
- Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
- Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
- Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
- Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
More ▼